NO974194L - Forbedringer i, eller vedrörende, organiske sammensetninger - Google Patents

Forbedringer i, eller vedrörende, organiske sammensetninger

Info

Publication number
NO974194L
NO974194L NO974194A NO974194A NO974194L NO 974194 L NO974194 L NO 974194L NO 974194 A NO974194 A NO 974194A NO 974194 A NO974194 A NO 974194A NO 974194 L NO974194 L NO 974194L
Authority
NO
Norway
Prior art keywords
organic compositions
granules
carbomer
salt
active agent
Prior art date
Application number
NO974194A
Other languages
English (en)
Other versions
NO974194D0 (no
Inventor
Peter Williams Dettmar
Paul Andrew Dickson
Frank Chadwick Hampson
Ian Gordon Jolliffe
William Peers
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Publication of NO974194D0 publication Critical patent/NO974194D0/no
Publication of NO974194L publication Critical patent/NO974194L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet mukoadhesive granuler innbefattende a) karbomerog/eller et salt derav; og b) et inert fyllstoff. Granulene irmbefatter videre fortrinnsvis et farmasøytisk aktivt middel egnet for vedvarende frigivelse i gastrointestinalkanalen eller for målrettet avlevering til den gastrointestinale slimhinnen.
NO974194A 1995-03-13 1997-09-11 Forbedringer i, eller vedrörende, organiske sammensetninger NO974194L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9505032.4A GB9505032D0 (en) 1995-03-13 1995-03-13 Improvements in or relating to organic compositions
PCT/GB1996/000514 WO1996028141A1 (en) 1995-03-13 1996-03-05 Improvements in or relating to organic compositions

Publications (2)

Publication Number Publication Date
NO974194D0 NO974194D0 (no) 1997-09-11
NO974194L true NO974194L (no) 1997-09-11

Family

ID=10771122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974194A NO974194L (no) 1995-03-13 1997-09-11 Forbedringer i, eller vedrörende, organiske sammensetninger

Country Status (20)

Country Link
US (1) US6306789B1 (no)
EP (1) EP0814771B1 (no)
JP (1) JPH11501652A (no)
KR (1) KR19980702970A (no)
CN (1) CN1126533C (no)
AT (1) ATE212539T1 (no)
AU (1) AU712464B2 (no)
BR (1) BR9607234A (no)
CZ (1) CZ274497A3 (no)
DE (1) DE69618934T2 (no)
ES (1) ES2167546T3 (no)
GB (2) GB9505032D0 (no)
HU (1) HUP9900800A3 (no)
MX (1) MX9706992A (no)
NO (1) NO974194L (no)
NZ (1) NZ302741A (no)
PL (1) PL184407B1 (no)
TR (1) TR199700943T1 (no)
WO (1) WO1996028141A1 (no)
ZA (1) ZA962012B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GB9809347D0 (en) * 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
IN190017B (no) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP3620153A1 (en) 2007-07-06 2020-03-11 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
HUE038452T2 (hu) 2007-11-13 2018-10-29 Meritage Pharma Inc Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók
US9050368B2 (en) * 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
DK2328553T3 (da) 2008-08-20 2020-08-24 Univ California Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
EP2968651B1 (en) * 2013-03-15 2020-10-21 Cook Medical Technologies LLC Adhesive medical products and methods for treating gastrointestinal lesions
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
WO2017019907A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
WO2019067680A1 (en) 2017-09-27 2019-04-04 Cook Medical Technologies Llc CROSSLINKING SUBMUCOSAL INJECTION SYSTEM
CA3087574A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114904007B (zh) * 2022-04-24 2024-04-05 南京紫鸿生物科技有限公司 一种提高卡波姆的堆积密度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60237054A (ja) 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
TW209174B (no) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
ES2145102T3 (es) * 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.

Also Published As

Publication number Publication date
BR9607234A (pt) 1997-11-11
GB2298790B (en) 1999-06-30
HUP9900800A3 (en) 2001-02-28
NZ302741A (en) 1999-08-30
ATE212539T1 (de) 2002-02-15
PL184407B1 (pl) 2002-10-31
TR199700943T1 (xx) 1998-02-21
GB2298790A (en) 1996-09-18
NO974194D0 (no) 1997-09-11
DE69618934T2 (de) 2002-09-12
AU712464B2 (en) 1999-11-04
ZA962012B (en) 1996-09-26
CZ274497A3 (cs) 1998-03-18
US6306789B1 (en) 2001-10-23
DE69618934D1 (de) 2002-03-14
PL322065A1 (en) 1998-01-05
GB9604678D0 (en) 1996-05-01
MX9706992A (es) 1997-11-29
HUP9900800A2 (hu) 1999-07-28
CN1126533C (zh) 2003-11-05
AU4886896A (en) 1996-10-02
GB9505032D0 (en) 1995-05-03
JPH11501652A (ja) 1999-02-09
WO1996028141A1 (en) 1996-09-19
HK1011291A1 (en) 1999-07-09
CN1178458A (zh) 1998-04-08
EP0814771B1 (en) 2002-01-30
ES2167546T3 (es) 2002-05-16
KR19980702970A (ko) 1998-09-05
EP0814771A1 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
NO974194D0 (no) Forbedringer i, eller vedrörende, organiske sammensetninger
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
NO20016108D0 (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
DE69732412D1 (de) Polares bukkales spray
DK1021204T3 (da) Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
AU3357800A (en) Method of preparing alkylated salicylamides
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
ATE515949T1 (de) Süssware
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
IS6337A (is) Lífhimnubindandi lyfjasamsetning til meðhöndlunará sáramyndun og/eða fleiðri í slímhimnuþekju
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
WO2003063823A3 (en) Osmotic delivery system
WO2004021985A3 (en) Verifiable absorption drug delivery form based on cyclodextrins
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
DK1200088T3 (da) Sammensætning indeholdende paracetamol og drotaverin
IT1263222B (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
CY1105165T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application